GlassScriptPhysician profile
Christie L Cotty
NPI 1013106715
$5,757.35
in general payments reported to CMS, 2019-2025
28 companies · $771 in 2025
The $771 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,615 · 2022: $1,660 · 2023: $1,044 · 2024: $666 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,550.98 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $739.98 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $518.67 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.57 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $294.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $253.51 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $249.07 | 2021 | |
| Idorsia Pharmaceuticals US INC | $235.21 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $234.89 | 2022-2025 | Airsupra |
| Abbvie INC. | $213.47 | 2021-2023 | |
| Inspire Medical Systems, INC. | $158.54 | 2024 | Inspire |
| Exact Sciences Corporation | $155.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $125.88 | 2021-2023 | |
| Glaxosmithkline, LLC. | $125.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $124.77 | 2023 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $66.80 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $62.67 | 2021-2022 | |
| Biogen, INC. | $62.38 | 2023 | |
| Astellas Pharma US INC | $59.54 | 2021-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $38.44 | 2021 | |
| Amarin Pharma, INC. | $33.27 | 2021-2023 | |
| Axsome Therapeutics, INC. | $30.93 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $25.99 | 2025 | Injectafer |
| Arbor Pharmaceuticals, INC. | $20.42 | 2021 | |
| Pharmacosmos Therapeutics INC. | $19.98 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.48 | 2021 | |
| Merck Sharp & Dohme LLC | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christie Cotty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.